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Protective roles of thioredoxin, a redox-regulating protein, in
renal ischemia/reperfusion injury.
Background. Thioredoxin (TRX) is a small protein with re-
dox-regulating functions. Although TRX is known to be in-
duced in response to various forms of oxidative stress, including
ischemia/reperfusion injury, the induction and the specific role
of this protein in the kidney have not been fully investigated.
Methods. Renal ischemia/reperfusion was induced by the
clipping and release of renal arteries in C57BL/6 and human
thioredoxin-overexpressing transgenic (hTRX-Tg) mice. TRX
protein was detected by immunohistochemistry, Western blot-
ting, and enzyme-linked immunosorbent assay (ELISA). TRX
mRNA was detected by in situ hybridization and Northern blot-
ting. Renal functions were evaluated by measuring the levels
of blood urea nitrogen and serum creatinine in these mice.
Results. With ischemia/reperfusion, endogenous murine TRX
was rapidly depleted from the cytosol in the cortical proximal
tubuli and detected in the urinary lumen, whereas it was spread
diffusely in all segments of the tubular epithelial cells in sham-
operated mice. The urinary excretion of TRX increased tran-
siently after ischemia/reperfusion and recovered to the control
level in 72 hours. In the medullary thick ascending limb (mTAL),
however, TRX was specifically retained in the cytosol. A similar
distribution change of transgenic hTRX was observed in the
kidney of hTRX-Tg. These hTRX-Tg mice were more resistant
to the injury to the mTAL and functional deterioration caused
by ischemia/reperfusion, compared with wild-type mice.
Conclusion. The present findings suggest that TRX is re-
tained in mTAL and secreted from proximal tubuli into urine
during renal ischemia/reperfusion. The mTAL-specific reten-
tion of TRX may have a protective effect against renal isch-
emia/reperfusion injury.
Renal ischemia/reperfusion is deeply involved in the
pathogenesis of acute or chronic renal failure and allo-
graft nephropathy [1–3]. The medullary thick ascending
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limb (mTAL) in the kidney is most vulnerable to isch-
emia and reperfusion, partly because of its great demand
for oxygen for adenosine triphosphate (ATP)-dependent
reabsorption in spite of a low oxygen supply [3]. Accumu-
lating evidence has shown that the production of reactive
oxygen species (ROS) and disruption of redox are inti-
mately associated with the pathophysiology of ischemia/
reperfusion injury [4, 5].
Thioredoxin (TRX) is a 12 kD protein, with a redox-
active dithiol/disulfide in the active site consensus se-
quence: -Cys-Gly-Pro-Cys-. TRX functions as an anti-
oxidant and as a redox-regulating protein in signal
transductions [6–10]. Human thioredoxin-overexpress-
ing transgenic mice (hTRX-Tg) had smaller cerebral in-
farcts than wild-type mice after cerebral artery occlusion
[11]. Studies on the brain and eye have shown that TRX
expression is augmented in areas most susceptible to
ischemia/hypoxia during ischemic insult [12, 13]. These
were observed at 16 hours or longer after ischemia/reper-
fusion, implying a de novo synthesis of TRX via the
induction of mRNA expression [14]. We report here that
murine endogenous TRX was rapidly depleted from the
cytosol in the cortical proximal tubuli and detected in
the urine after ischemia/reperfusion. In contrast, TRX
was specifically retained in the mTAL without mRNA
induction. A similar translocation of transgenic hTRX
was observed in hTRX-Tg mice. Compared with wild-
type mice, hTRX-Tg mice were resistant to the injury
to the mTAL and functional deterioration caused by
ischemia/reperfusion. TRX may play an important role
in protecting against renal ischemia/reperfusion injury.
METHODS
Animals and protocol
The generation of hTRX-Tg mice from C57BL/6 mice,
with a transgene composed of the -actin promoter and
hTRX gene, has been described previously [11]. The
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presence of the transgene was confirmed by polymerase
chain reaction (PCR) and Western blotting. The hTRX
protein encoded by this transgene is functionally equiva-
lent to murine TRX [11]. Intracellular levels of hTRX
are substantially higher (three- to tenfold) in several
tissues and around fivefold higher in the kidney than
endogenous murine TRX levels in the hTRX-Tg mice
[11]. Female hTRX transgenic and C57BL/6 wild-type
mice, weighing 25 to 30 g, were placed under general
anesthesia with intraperitoneal pentobarbital (50 mg/kg
body weight). Through retroperitoneal incisions, bilat-
eral renal arteries were clipped for 30 minutes then re-
leased. The harvested kidneys were frozen in liquid nitro-
gen or immersed in 10% neutral-buffered formaldehyde,
and embedded in paraffin. Sham-operated mice were
treated as above, but without clipping and release of the
arteries. All mice were handled in accordance with the
Guiding Principles for the Care and Use of Experimental
Animals of Kyoto University.
Antibody
Anti-hTRX monoclonal antibody, which does not
cross-react with murine TRX, was described elsewhere
[11] and provided by Redox Bioscience, Inc., Kyoto,
Japan. The antimouse TRX polyclonal antibody was pu-
rified from the serum of a rabbit immunized with recom-
binant murine TRX (Redox Bioscience, Inc.). Full-
length soluble recombinant murine TRX was suspended
in saline and emulsified by mixing with an equal volume
of complete Freund’s adjuvant. It was injected into three
to four subcutaneous dorsal sites of New Zealand white
rabbits, 3 to 9 months old, for the primary immunization.
Subsequent immunizations were performed using incom-
plete Freund’s adjuvant. After immunization three times,
the animals were bled from the auricular artery. The
blood was allowed to clot and serum was collected by
centrifugation. The polyclonal antibody reactive with the
recombinant murine TRX was further purified by an
affinity column with the antigen peptide coupled to Affi-
Gel 10 (Bio-Rad, Hercules, CA, USA). These antibodies
do not cross-react with the mitochondrial form of TRX
(TRX-2) [15].

Fig. 1. Immunohistochemistry for thioredoxin (TRX) in kidneys. (A ) Distribution of TRX in sham-operated mice. Immunoreactivity for TRX
was spread diffusely throughout the tubuli, and the intensity was strong in the cortex and weak in the medulla. (B ) Higher magnification view of
the outer medulla in sham-operated mice. TRX immunoreactivity was spread evenly in the cytosol of outer medullary tubuli. (C ) Negative control.
Kidney of sham-operated mice was stained with antimurine TRX antibody preincubated with recombinant murine TRX used as immunogen. No
significant staining was observed. (D ) Distribution of TRX immediately after renal ischemia/reperfusion. TRX immunoreactivity was predominantly
observed in the outer medullary tubuli. (E ) Higher magnification view of the outer medulla in the mouse immediately after renal ischemia/
reperfusion. Intensive immunoreactivity for TRX was observed in the medullary thick ascending limb. (F ) Negative control. Kidney with ischemia/
reperfusion was stained with antimurine TRX antibody preincubated with recombinant murine TRX used as immunogen. The significant staining
in the medullary thick ascending limb was abolished by the preincubation with recombinant TRX. (G ) Distribution of human TRX (hTRX) in
sham-operated human thioredoxin-overexpressing transgenic (hTRX-Tg) mice. Immunoreactivity for hTRX was spread diffusely throughout the
tubuli. (H ) Distribution of hTRX in hTRX-Tg mice immediately after renal ischemia/reperfusion. hTRX immunoreactivity was predominantly
observed in the outer medullary tubuli (original magnification 40 in A, D, G, and H; 200 in B, C, E, and F). Abbreviations are: Co, cortex;
OM, outer medulla; IM, inner medulla; AL, thick ascending limb; and DL, thin descending limb.
Immunohistochemistry
Paraffin-embedded kidney tissue sections were de-
waxed and treated with hydrogen peroxide in methanol
to inactivate endogenous peroxidase activity. For detec-
tion of murine endogenous TRX, the sections were incu-
bated with antimouse TRX polyclonal antibody or non-
specific rabbit immunoglobulin G (IgG) for negative
controls for 60 minutes at room temperature after an
incubation with 5% goat serum to block nonspecific anti-
body binding. The sections were then incubated with
biotinylated antirabbit IgG from Universal Rabbit Sys-
tem (Biomeda, Foster City, CA, USA). For detection
of hTRX, the sections were incubated with anti-hTRX
monoclonal antibody or nonspecific mouse IgG for nega-
tive controls, followed by biotinylated antimouse IgG
from Universal Mouse System (Biomeda).
Western blot analysis
The whole kidneys with or without ischemia/reperfu-
sion were lysed using an Astrason (Misonix, Farming-
dale, NY) with lysis buffer [0.5% Nonided P-40, 10
mmol/L Tris-HCl, pH 7.5, 150 mmol/L NaCl, 1 mmol/L
phenylmethylsufonyl fluoride (PMSF), and 0.11 trypsin
inhibitor unit (TIU)/mL aprotinin]. Ten micrograms of
each lysate was subjected to electrophoresis under reduc-
ing conditions on a 15% sodium dodecyl sulfate (SDS)
polyacrylamide gel and then electrophretically trans-
ferred to a polyvinylidene difluoride membrane (Milli-
pore, Bedford, MA, USA). The membrane was blocked
with 10% skim milk in phosphate-buffered saline (PBS)
at 4C overnight and then incubated with anti-hTRX or
antimouse TRX antibody. Peroxidase-labeled antimouse
IgG and antirabbit IgG were used for detecting hTRX
and mouse TRX, respectively. Detection by chemilumi-
nescence was performed with an ECL Western blot de-
tection kit (Amersham, Little Chalfont, Buckingham-
shire, UK) according to the directions supplied [16].
Northern blot analysis
Total RNA was prepared from whole kidney with or
without ischemia/reperfusion by guanidium thiocyanate
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Fig. 2. Expression of thioredoxin (TRX) in
human thioredoxin-overexpressing transgenic
(hTRX-Tg) and wild-type (WT) mice. (A )
Western analysis of TRX in total kidneys.
Ischemia/reperfusion (I/R) was induced by clip-
ping for 30 minutes and then releasing the
renal artery. Total kidneys were harvested and
lysed quickly at the time indicated after the
ischemia/reperfusion. The amount of trans-
genic human TRX (hTRX) and intrinsic mu-
rine TRX (mTRX) was quantified by immu-
noblotting. (B, C ) Quantification of TRX in
total kidneys. Results are expressed as fold-
decrease relative to levels of TRX expression
in sham-operated mice.
extraction. Northern blot analysis was performed as pre-
viously described [16].
In situ hybridization
The antisense RNA probe was made from mouse TRX
cDNA and in situ hybridization was performed as re-
ported previously [16].
Measurement of urinary hTRX
Urine from hTRX-Tg mice with or without ischemia/
reperfusion was collected using metabolic cages (META-
BOLICA, Tokyo, Japan) and quickly frozen in liquid
nitrogen until use. The urinary concentration of hTRX
was measured by enzyme-linked immunosorbent assay
(ELISA) as previously described with minor modifica-
tion [17]. 3,3, 5,5-Tetramethylbenzidine was used as a
substrate for peroxidase and 30 minutes later, stopping
solution (2N H2SO4) was added. The absorption at OD450
nm was measured with an ELISA reader (Molecular
Devices, Menlo Park, CA, USA). Urinary levels of total
protein were measured by DC protein assay (Bio-Rad
Laboratories, Hercules, CA, USA).
Evaluation of renal functions
The concentration of blood urea nitrogen (BUN) and
serum creatinine was measured on commission by SRL,
Inc., Japan in hTRX-Tg and wild-type mice with or with-
out ischemia/reflow.
RESULTS
Rapid change in TRX immunoreactivity following
ischemia/reperfusion
We first investigated the immunolocalization of TRX
protein in the kidneys of C57BL/6 mice. In the sham-
operated mice, the immunoreactivity for TRX was spread
diffusely (Fig. 1 A to C) as previously reported [18].
Immediately after renal ischemia/reperfusion, the immu-
noreactivity was predominantly detected in the outer
medulla and decreased in other parts (Fig. 1D). In the
outer medulla, the immunoreactivity for TRX was
mainly observed in the cytosol of the mTAL (Fig. 1 E
and F). When we examined the immunolocalization of
glutaredoxin, which is a member of the TRX superfamily,
we found that the immunoreactivity for glutaredoxin was
spread diffusely and relatively stronger in the cortex than
in the medulla, and was unchanged after renal ischemia/
reperfusion (data not shown).
Immunohistochemistry for hTRX in the hTRX-Tg
mice revealed that transgenic hTRX was stained simi-
larly to intrinsic murine TRX in sham-operated mice
(Fig. 1G) and after renal ischemia/reperfusion (Fig. 1H).
Transgenic hTRX as well as intrinsic murine TRX was
predominantly observed in the outer medulla after renal
ischemia/reperfusion.
Expression of TRX in total kidney of hTRX-Tg and
wild-type mice
Western analysis of total kidney showed that hTRX-
Tg mice expressed both transgenic hTRX and intrinsic
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Fig. 3. Expression of thioredoxin (TRX)
mRNA. (A ) Localization of TRX mRNA in
sham-operated mice. In situ hybridization
in the sham-operated C57BL/6 mouse kid-
ney showed that positive signal had spread
throughout the tubuli. (B ) Localization of
TRX mRNA in the C57BL/6 mouse immedi-
ately after renal ischemia/reperfusion (I/R).
The positive signal had spread throughout the
tubuli. (C ) Negative control. Tissue of sham-
operated C57BL/6 mouse kidney was hybrid-
ized with the control probe. No signal was
noted (original magnification, 100). Abbre-
viations are: Co, cortex; OM, outer medulla;
and IM, inner medulla. (D ) Quantification of
TRX mRNA. Total RNA was isolated from
the cortex of the kidney immediately after
sham operation or renal ischemia/reperfusion.
The RNA was subjected to Northern blotting
and hybridized with 32P-labeled antisense
probe for TRX. Abbreviations are: WT, wild-
type; Tg, transgenic; mTRX, murine TRX.
murine TRX, whereas wild-type mice expressed only
intrinsic murine TRX (Fig. 2A). Renal ischemia/reperfu-
sion decreased slightly the expressions of both hTRX
and murine TRX in hTRX-Tg mice (Fig. 2B) and murine
TRX in wild-type mice (Fig. 2C).
Expression of TRX mRNA with renal
ischemia/reperfusion
To clarify whether transcriptional regulation is in-
volved in the redistribution of TRX in the kidney imme-
diately after ischemia/reperfusion, we next examined the
mRNA expression by in situ hybridization and Northern
blotting in the C57BL/6 and hTRX-Tg mouse kidneys. In
sham-operated C57BL/6 mice, TRX mRNA was spread
diffusely in all segments of the tubuli (Fig. 3A). Immedi-
ately after renal ischemia/reperfusion, the mRNA levels
remained unchanged throughout the tubuli (Fig. 3B).
The distribution of hTRX mRNA expression of the
hTRX-Tg mouse kidney was also unchanged. The quan-
tity of TRX mRNA from whole kidney was also un-
changed by the ischemia/reperfusion in both C57BL/6
and hTRX-Tg mouse kidneys (Fig. 3D).
Segment-specific retention and excretion of TRX
with reperfusion
An examination of the mechanism behind the rapid
change in distribution revealed that the immunoreactiv-
ity for TRX appeared on the apical side of the cortical
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Fig. 5. Urinary excretion of thioredoxin (TRX) with ischemia/reperfu-
sion. (A ) Urinary levels of TRX before and after ischemia/reperfusion.
Urinary levels of TRX were measured by enzyme-linked immunosor-
bent assay (ELISA) at the times indicated (N  6). (B ) Urinary levels
of total protein before and after ischemia/reperfusion. Urinary levels
of total protein were measured at the times indicated (N  6).
tubular cytosol immediately after renal ischemia/reper-
fusion (Fig. 4A). After the reperfusion, TRX was translo-
cated from the cytosol to the urinary lumen and nucleus
in the proximal tubular cells (Fig. 4B), while it was re-
tained in the mTAL (Fig. 4C). To quantify the amount
of TRX in the kidney with and without ischemia/reperfu-
sion, we conducted Western blot analysis in C57BL/6
and hTRX-Tg mice. Compared with the sham-operation,

Fig. 4. Mechanism of the rapid change in the distribution of thioredoxin (TRX). (A ) Cortex in the C57BL/6 mouse immediately after renal
ischemia/reperfusion (I/R). TRX immunoreactivity was observed unevenly on the apical side of the proximal tubuli (arrows). (B ) Cortical tubular
epithelial cells 1 hour after ischemia/reperfusion. TRX was decreased in the cytosol of the cortical proximal tubule and appeared in the urinary
lumen of the tubuli (arrows) and nucleus. TRX immunoreactivity was observed in the cytosol of the distal tubular cells (arrowheads). (C ) Outer
medulla 1 hour after ischemia/reperfusion. TRX immunoreactivity was observed in the cytosol of the medullary thick ascending limb and thin
descending limb (original magnification, 400 in A and B; 200 in C). Abbreviations are: P, proximal tubule; D, distal tubule; AL, thick ascending
limb; and DL, thin descending limb. (D ) Quantification of intrarenal TRX. Ischemia/reperfusion was induced by clipping for 30 minutes and then
releasing the renal artery of C57BL/6 mice. Kidneys were then cut and divided into the cortex and the outer medulla, and lysed quickly 30 minutes
after the reperfusion. The amount of TRX in the lysate was quantified by immunoblotting. Results shown are representative of three independent
examinations with similar results.
ischemia/reperfusion caused a 50% decrease of TRX in
the cortex of the kidney but no change in the outer
medulla (Fig. 4D). Western blot analysis in the hTRX-
Tg mice revealed that hTRX was also lost in the cortex
and retained in the outer medulla of the kidney with
ischemia/reperfusion like intrinsic murine TRX above
(data not shown). The total decrease of TRX shown in
Figure 2 may be explained by that the loss of TRX in
the cortex was greater than the retained amount of TRX
in the outer medulla.
Transient increase in urinary TRX excretion
with reperfusion
To pursue the lost TRX in the cortical proximal tubuli,
the urinary hTRX of hTRX-Tg mice was quantified be-
fore and after ischemia/reperfusion by ELISA. The con-
centration of hTRX was 3.4  4.0 ng/mL before the
insult; however, this increased to 486.4  404.3 ng/mL
in the first (12 hours) urine after the reperfusion, and
then recovered to the control level after 72 hours (Fig.
5A). Urine from hTRX-Tg mice contained both trans-
genic hTRX and intrinsic murine TRX, whereas that
from wild-type mice contained only intrinsic murine
TRX, which was also increased transiently after reperfu-
sion (data not shown). To investigate whether urinary
excretion of TRX was specific, we quantified the excre-
tion of total protein before and after ischemia/reperfu-
sion. The excretion of urinary total protein was un-
changed after ischemia/reperfusion. (Fig. 5B).
Attenuation of reperfusion-induced mTAL injury and
renal dysfunction by hTRX overexpression
To analyze the role of the rapid change in the local-
ization of TRX in renal reperfusion injury, we then
compared the histology of the kidney with 30 minutes
ischemia following 24 hours reperfusion between the
hTRX-Tg and wild-type mice. In the sham-operated
mice, there was no renal damage in wild-type or hTRX-
Tg animals. After the reperfusion, the outer medulla was
specifically injured in the wild-type mice. Most of the
tubular epithelial cells in the mTAL were detached from
the basement membrane, and the nucleus of these cells
disappeared (Fig. 6A), whereas the cortical tubuli were
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Fig. 6. Histology of reperfusion injury in
human thioredoxin-overexpressing transgenic
(hTRX-Tg) and wild-type (WT) mice. (A )
Kidney of wild-type mouse 24 hours after 30
minutes ischemia/reperfusion (I/R). The epi-
thelial cells of the medullary thick ascending
limb (mTAL) detach from the basement
membrane (arrow) and become sparse. The
detached cells appear to be homogenously eo-
sinophilic in the cytoplasm, and karyolysis and
loss of chromatin are found in the nuclei. (B )
Cortex of the wild-type mouse kidney 24 hours
after 30 minutes ischemia/reperfusion. Some
tubuli were flattened; however, neither cell
detachment nor karyolysis was found in the
cortical tubular epithelial cells. (C ) Kidney
of hTRX-Tg mice after 30 minutes ischemia/
reperfusion. Tubular cells of the mTAL re-
main adhered to the basement membrane and
the density of the cell population is preserved.
(D ) Cortex of the hTRX-Tg mouse kidney 24
hours after 30 minutes ischemia/reperfusion.
Some tubuli were flattened, however, neither
cell detachment nor karyolysis was found in
the cortical tubular epithelial cells. Hematoxy-
lin and eosin (original magnification, 200).
(E ) Percentages of detached cells. The cells
were counted in specimens sectioned along
the sagittal midline, and containing more than
10 cells. The percentage of cells detached
from the basement membrane was calculated.
TRX-Tg is TRX transgenic mice. *P  0.0001
(N  6).
adhered intact to the basement membrane (Fig. 6B). On
the other hand, in the hTRX-Tg mice after the reperfu-
sion, the injury to the mTAL was remarkably suppressed
(Fig. 6C and E).
To assess the renal function, the levels of serum creati-
nine and BUN were measured in the hTRX-Tg and wild-
type mice. There was no significant difference in either
level between the hTRX-Tg and wild-type mice before
ischemic treatment. However, the serum creatinine level
after ischemia/reperfusion was significantly lower in the
hTRX-Tg than wild-type mice (0.10  0.00 mg/dL and
0.16  0.05 mg/dL, respectively, P  0.040, N  6) (Fig.
7A). The BUN levels after ischemia/reperfusion were
also significantly lower in the hTRX-Tg than wild-type
mice (22.4  4.5 mg/dL and 29.2  1.3 mg/dL, respec-
tively, P  0.005, N  6) (Fig. 7B).
DISCUSSION
In the present study, we found that after renal ische-
mia/reperfusion the immunoreactivity for TRX is rapidly
redistributed to the outer medulla, the area most vulner-
able to ischemia/reperfusion [3]. The topologic retention
of TRX in the most vulnerable portion in the kidney may
be meaningful in the host defense mechanism against
ischemia/reperfusion injury. Previous studies have shown
that various forms of oxidative stress increase levels of
TRX mRNA 16 hours after induction [14, 19]. However,
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Fig. 7. Renal function after reperfusion in human thioredoxin-over-
expressing transgenic (hTRX-Tg) and wild-type (WT) mice. (A ) The
serum concentration of creatinine was measured in the hTRX-Tg and
wild-type mice with or without ischemia/reperfusion (I/R). For ischemia/
reperfusion, the renal arteries were clipped for 30 minutes and reper-
fused. Sera were harvested at 24 hours after the reperfusion. (B ) The
concentration of blood urea nitrogen was measured in the sera of the
hTRX-Tg and wild-type mice. *P  0.05; **P  0.01.
in our study, the ischemia/reperfusion did not change
the mRNA expression of TRX, suggesting that a post-
translational control is involved in the rapid change of
TRX immunoreactivity by ischemia/reperfusion. The post-
translational controls are crucial under emergency situa-
tions, so that cells can efficiently respond to rapid envi-
ronmental changes and metabolic requirements [20, 21].
We demonstrated that the overexpression of hTRX
in transgenic mice attenuated the reperfusion injury to
the mTAL. The retention of transgenic hTRX as well as
intrinsic murine TRX in the vulnerable segments of tu-
buli during ischemia/reperfusion may explain the mech-
anism of renal protection by TRX overexpression. TRX
as well as glutathione plays an important role in the
host defense mechanism against oxidative stress. Proximal
tubule cells are known to contain high amounts of gluta-
thione [22] and we observed that the distribution of glu-
taredoxin was unchanged by ischemia/reperfusion in the
present study. These results suggest that the selective
retention of TRX in the outer medulla is quite reason-
able in the host defense mechanism against renal ische-
mia/reperfusion injury.
After the reperfusion, the mTAL retained TRX, while
the cortical proximal tubuli lost it. TRX is known to be
secreted by a variety of cells in response to oxidative
stress [6]; however, the urinary excretion of TRX has
not yet been reported. Here we observed that TRX levels
were elevated in the urinary lumen of cortical proximal
tubuli and in urine after reperfusion. These results sug-
gest that the altered redistribution of TRX after renal
ischemia/reperfusion can be explained by the excretion
into the urine from cortical proximal tubuli. TRX is
excreted into urine in healthy individuals, and increased
urinary TRX levels are associated with some renal dis-
eases (data not shown). The excretion of TRX may not
be due to leakage from dead cells since total protein
levels were unchanged in the urine after the reperfusion.
These findings suggest that urinary TRX may be a useful
marker for renal ischemia/reperfusion injury and oxida-
tive stress. The exact role of urinary TRX is currently
unknown. However, previous reports suggest that extra-
cellular TRX also has a protective role against oxidative
injury. Extracellularly injected recombinant hTRX has
a protective effect on arrhythmia [23], and injury to the
lung [24, 25], neuronal cells [26], and retina [27, 28]
induced by ischemia/reperfusion. Moreover, extracellu-
lar TRX is able to be uptaken by cells and the dithiol-
disulfide oxidoreductase activity of TRX is likely to be
involved in its extracellular function [29].
CONCLUSION
The present study demonstrates that TRX is retained
in the mTAL and secreted from proximal tubuli to urine
during renal ischemia/reperfusion. Compared with wild-
type mice, hTRX-Tg mice were resistant to the damage
to the mTAL caused by renal ischemia/reperfusion. To
improve the prognosis for hypoxia/ischemia/reperfusion
injury, a variety of agents, including radical scavengers,
have been tested. However, very few have consistently
been shown to be beneficial for renal ischemia/reperfu-
sion injury [30]. This current study suggests that TRX
plays a protective role in the early phase of ischemia/
reperfusion. Recent reports have shown that geranylger-
anylacetone (GGA) induces the expression of TRX and
pretreatment with GGA protects cells from oxidative
stress [31–33]. TRX and TRX-inducing drugs may be
promising candidates for therapeutics to improve the
prognosis of renal ischemic injury.
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